The quarter came in slightly worse than the market expected. Biohaven reported adjusted EPS of -$0.78 versus published estimates clustered around roughly -$0.74 to -$0.76, while GAAP EPS was -$0.91. The miss is narrow, but this is a development-stage biotech with no product revenue, so the key question is spending, financing capacity, and clinical progress rather than sales growth.
| Metric | Q2 2026 | Q2 2025 | Market read |
|---|---|---|---|
| GAAP net loss | $137.3 million | $198.1 million | Lower loss year over year, but EPS miss due partly to share count growth (Income Statement) |
| GAAP loss per share | $0.91 | $1.94 | Better year over year; still worse than published consensus (Income Statement) |
| Adjusted net loss | $118.1 million | $166.4 million | Operating loss improved, broadly near expectations (GAAP to Non-GAAP reconciliation) |
| Adjusted loss per share | $0.78 | $1.63 | Narrowly below consensus (GAAP to Non-GAAP reconciliation) |
| R&D expense | $100.8 million | $184.4 million | Major reduction after program reprioritization (R&D Expenses) |
| Cash and marketable securities | $267.9 million at June 30 | $319.1 million at December 31 | Liquidity declined despite lower spending (Balance Sheet) |
| Notes payable | $259.5 million at June 30 | $238.9 million at December 31 | Debt increased as equity fell (Balance Sheet) |
Cost control is the clearest financial positive, but it is not entirely new. R&D fell 45% year over year to $100.8 million, primarily because of the strategic reprioritization implemented in the fourth quarter of 2025 and the absence of prior-year developmental milestone payments (R&D Expenses). That reduction helped shrink the adjusted net loss by about $48 million, but it largely reflects previously announced portfolio discipline rather than a new acceleration in operating leverage.
The clinical update is constructive but mostly confirms an existing narrative. BHV-1300 produced more than 80% mean reductions in disease-driving antibodies in Graves’ disease and has entered pivotal development; BHV-1400 showed more than 60% reductions in pathogenic Gd-IgA1 within 48 hours; and opakalim continued to show seizure-control and tolerability signals (Graves’ disease program; IgA nephropathy program; Opakalim clinical update). Those data support the company’s platform thesis, but much of the information was already presented in May 2026, making this filing more of a progress recap than a fresh upside catalyst.
The balance sheet keeps the read from being more positive. Cash plus marketable securities fell to $267.9 million from $319.1 million at December 31, while notes payable rose to $259.5 million and shareholders’ equity declined to only $12.2 million (Balance Sheet). The release gives no new explicit cash-runway target or financing commitment, so the lower burn rate is helpful but does not remove funding pressure as multiple pivotal programs advance.
Net: a modest earnings miss against a generally intact pipeline story. The filing delivers better cost control and several clinically encouraging milestones, but those positives were largely known, while the headline adjusted loss was slightly worse than consensus and liquidity weakened. That makes the overall event narrowly negative versus expectations rather than a meaningful change in the investment narrative.
Read the original 8-K on SEC EDGAR ↗